Tissue | Expression Dynamics | Abbreviation |
Breast | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Breast/NFKBIA_pca_on_diff_genes.png) | IDC: Invasive ductal carcinoma |
DCIS: Ductal carcinoma in situ |
Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers |
Cervix | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Cervix/NFKBIA_pca_on_diff_genes.png) | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/NFKBIA_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/NFKBIA_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Endometrium | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Endometrium/NFKBIA_pca_on_diff_genes.png) | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/NFKBIA_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
GC | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/GC/NFKBIA_pca_on_diff_genes.png) | CAG: Chronic atrophic gastritis |
CAG with IM: Chronic atrophic gastritis with intestinal metaplasia |
CSG: Chronic superficial gastritis |
GC: Gastric cancer |
SIM: Severe intestinal metaplasia |
WIM: Wild intestinal metaplasia |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/NFKBIA_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/NFKBIA_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/NFKBIA_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/NFKBIA_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/NFKBIA_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/NFKBIA_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:005123531 | Oral cavity | NEOLP | maintenance of location | 62/2005 | 327/18723 | 5.41e-06 | 1.12e-04 | 62 |
GO:000223731 | Oral cavity | NEOLP | response to molecule of bacterial origin | 67/2005 | 363/18723 | 5.94e-06 | 1.20e-04 | 67 |
GO:004518531 | Oral cavity | NEOLP | maintenance of protein location | 25/2005 | 94/18723 | 1.25e-05 | 2.25e-04 | 25 |
GO:190370632 | Oral cavity | NEOLP | regulation of hemopoiesis | 66/2005 | 367/18723 | 1.67e-05 | 2.83e-04 | 66 |
GO:005117031 | Oral cavity | NEOLP | import into nucleus | 35/2005 | 159/18723 | 2.54e-05 | 3.99e-04 | 35 |
GO:001703831 | Oral cavity | NEOLP | protein import | 42/2005 | 206/18723 | 2.98e-05 | 4.54e-04 | 42 |
GO:000660631 | Oral cavity | NEOLP | protein import into nucleus | 34/2005 | 155/18723 | 3.55e-05 | 5.20e-04 | 34 |
GO:003806131 | Oral cavity | NEOLP | NIK/NF-kappaB signaling | 31/2005 | 143/18723 | 9.70e-05 | 1.18e-03 | 31 |
GO:000222121 | Oral cavity | NEOLP | pattern recognition receptor signaling pathway | 35/2005 | 172/18723 | 1.38e-04 | 1.60e-03 | 35 |
GO:007042322 | Oral cavity | NEOLP | nucleotide-binding oligomerization domain containing signaling pathway | 10/2005 | 25/18723 | 1.39e-04 | 1.61e-03 | 10 |
GO:005109031 | Oral cavity | NEOLP | regulation of DNA-binding transcription factor activity | 72/2005 | 440/18723 | 1.66e-04 | 1.84e-03 | 72 |
GO:003587221 | Oral cavity | NEOLP | nucleotide-binding domain, leucine rich repeat containing receptor signaling pathway | 10/2005 | 26/18723 | 2.04e-04 | 2.19e-03 | 10 |
GO:000276422 | Oral cavity | NEOLP | immune response-regulating signaling pathway | 74/2005 | 468/18723 | 3.90e-04 | 3.63e-03 | 74 |
GO:000275321 | Oral cavity | NEOLP | cytoplasmic pattern recognition receptor signaling pathway | 16/2005 | 60/18723 | 4.28e-04 | 3.91e-03 | 16 |
GO:004563724 | Oral cavity | NEOLP | regulation of myeloid cell differentiation | 39/2005 | 210/18723 | 4.32e-04 | 3.93e-03 | 39 |
GO:190122231 | Oral cavity | NEOLP | regulation of NIK/NF-kappaB signaling | 24/2005 | 112/18723 | 6.77e-04 | 5.63e-03 | 24 |
GO:007043112 | Oral cavity | NEOLP | nucleotide-binding oligomerization domain containing 2 signaling pathway | 7/2005 | 16/18723 | 7.62e-04 | 6.16e-03 | 7 |
GO:007122231 | Oral cavity | NEOLP | cellular response to lipopolysaccharide | 38/2005 | 209/18723 | 7.74e-04 | 6.23e-03 | 38 |
GO:003134922 | Oral cavity | NEOLP | positive regulation of defense response | 47/2005 | 278/18723 | 1.05e-03 | 7.99e-03 | 47 |
GO:000721921 | Oral cavity | NEOLP | Notch signaling pathway | 32/2005 | 172/18723 | 1.31e-03 | 9.48e-03 | 32 |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0517118 | Breast | Precancer | Coronavirus disease - COVID-19 | 81/684 | 232/8465 | 3.74e-32 | 2.36e-30 | 1.81e-30 | 81 |
hsa0520818 | Breast | Precancer | Chemical carcinogenesis - reactive oxygen species | 68/684 | 223/8465 | 3.61e-23 | 1.14e-21 | 8.73e-22 | 68 |
hsa0513218 | Breast | Precancer | Salmonella infection | 49/684 | 249/8465 | 2.92e-09 | 6.15e-08 | 4.71e-08 | 49 |
hsa0513414 | Breast | Precancer | Legionellosis | 19/684 | 57/8465 | 4.62e-08 | 9.12e-07 | 6.98e-07 | 19 |
hsa0513018 | Breast | Precancer | Pathogenic Escherichia coli infection | 38/684 | 197/8465 | 3.12e-07 | 5.81e-06 | 4.45e-06 | 38 |
hsa0513118 | Breast | Precancer | Shigellosis | 44/684 | 247/8465 | 3.91e-07 | 6.86e-06 | 5.26e-06 | 44 |
hsa0516718 | Breast | Precancer | Kaposi sarcoma-associated herpesvirus infection | 36/684 | 194/8465 | 1.68e-06 | 2.53e-05 | 1.94e-05 | 36 |
hsa0541718 | Breast | Precancer | Lipid and atherosclerosis | 37/684 | 215/8465 | 7.64e-06 | 9.29e-05 | 7.12e-05 | 37 |
hsa0516918 | Breast | Precancer | Epstein-Barr virus infection | 35/684 | 202/8465 | 1.15e-05 | 1.26e-04 | 9.64e-05 | 35 |
hsa0465716 | Breast | Precancer | IL-17 signaling pathway | 20/684 | 94/8465 | 4.74e-05 | 4.54e-04 | 3.48e-04 | 20 |
hsa042108 | Breast | Precancer | Apoptosis | 25/684 | 136/8465 | 7.61e-05 | 6.87e-04 | 5.26e-04 | 25 |
hsa0516618 | Breast | Precancer | Human T-cell leukemia virus 1 infection | 33/684 | 222/8465 | 4.29e-04 | 3.31e-03 | 2.53e-03 | 33 |
hsa0516316 | Breast | Precancer | Human cytomegalovirus infection | 32/684 | 225/8465 | 1.13e-03 | 7.57e-03 | 5.80e-03 | 32 |
hsa051206 | Breast | Precancer | Epithelial cell signaling in Helicobacter pylori infection | 14/684 | 70/8465 | 1.21e-03 | 7.99e-03 | 6.12e-03 | 14 |
hsa052036 | Breast | Precancer | Viral carcinogenesis | 27/684 | 204/8465 | 7.19e-03 | 4.06e-02 | 3.11e-02 | 27 |
hsa0517119 | Breast | Precancer | Coronavirus disease - COVID-19 | 81/684 | 232/8465 | 3.74e-32 | 2.36e-30 | 1.81e-30 | 81 |
hsa0520819 | Breast | Precancer | Chemical carcinogenesis - reactive oxygen species | 68/684 | 223/8465 | 3.61e-23 | 1.14e-21 | 8.73e-22 | 68 |
hsa0513219 | Breast | Precancer | Salmonella infection | 49/684 | 249/8465 | 2.92e-09 | 6.15e-08 | 4.71e-08 | 49 |
hsa0513415 | Breast | Precancer | Legionellosis | 19/684 | 57/8465 | 4.62e-08 | 9.12e-07 | 6.98e-07 | 19 |
hsa0513019 | Breast | Precancer | Pathogenic Escherichia coli infection | 38/684 | 197/8465 | 3.12e-07 | 5.81e-06 | 4.45e-06 | 38 |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
4792 | NFKBIA | CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR BINDING, DRUGGABLE GENOME | | 6-METHOXYCOMAPARVIN | CHEMBL401565 | 18088098 |
4792 | NFKBIA | CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR BINDING, DRUGGABLE GENOME | | 6-METHOXYCOMAPARVIN 5-METHYL ETHER | CHEMBL256967 | 18088098 |
4792 | NFKBIA | CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR BINDING, DRUGGABLE GENOME | | DEMETHYLWEDELOLACTONE | DEMETHYLWEDELOLACTONE | 22926226 |
4792 | NFKBIA | CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR BINDING, DRUGGABLE GENOME | | GAMBOGIC ACID | GAMBOGIC ACID | 22472167 |
4792 | NFKBIA | CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR BINDING, DRUGGABLE GENOME | | gefitinib | GEFITINIB | 31664190 |
4792 | NFKBIA | CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR BINDING, DRUGGABLE GENOME | | (+)-TUBERIFERIN | CHEMBL1940084 | 22153345 |
4792 | NFKBIA | CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR BINDING, DRUGGABLE GENOME | | WEDELOLACTONE | WEDELOLACTONE | 22926226 |
4792 | NFKBIA | CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR BINDING, DRUGGABLE GENOME | | DIOSCIN | DIOSCIN | 23621869 |
4792 | NFKBIA | CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR BINDING, DRUGGABLE GENOME | | PEPEROMIN E | PEPEROMIN E | 19559609 |